根据分析师分享的艾昆纬最新数据，在截至5月1日的一周内，礼来公司减肥药物Foundayo在美国市场的处方量达到7335份。这一数字显示出该药物在医疗减肥领域的市场渗透力正在稳步提升。
处方数据的持续追踪为投资者评估减肥药物市场格局提供了关键指标。随着全球肥胖症患病率的上升，礼来与诺和诺德等制药巨头在GLP-1受体激动剂领域的竞争日趋白热化。Foundayo作为礼来产品组合中的重要成员，其处方趋势直接反映了公司在该细分市场的战略布局成效。
医疗保健分析师指出，周度处方数据是观测药物商业化进展的灵敏指标。7335份的周处方量不仅体现了医生群体对该疗法的认可度，也预示着未来季度营收的增长潜力。当前美国减肥药物市场年规模已突破百亿美元，且保持双位数增长率，这使得各家药企的市占率变化备受资本市场关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.